Altaris to Acquire Simulations Plus for $375 Million to Expand Healthcare Software Portfolio

On June 16, 2026, healthcare private equity firm Altaris announced an agreement to acquire Simulations Plus for approximately $375 million in cash. Simulations Plus is a drug development software provider, specializing in model-informed and AI-accelerated drug development advancing biopharma innovation.

According to Altaris, the transaction will transition Simulations Plus into a privately held entity and result in its delisting from the Nasdaq Global Select Market. Simulations Plus shareholders will receive $18.50 per share in cash, representing a 26 percent premium over the 60-day average share price.

“The life sciences industry is at an inflection point, as software and services are rapidly evolving toward integrated, AI-driven platforms, cloud-based infrastructure, and more predictable, subscription-based business models. This transaction provides immediate and certain value to Simulations Plus stockholders, and we believe the transaction will better position us to serve our customers and accelerate innovation across product offerings.” said Shawn O’Connor, Chief Executive Officer of Simulations Plus.

Platform Integration and Synergy

As per Altaris, the transaction is part of its broader commitment to investing in digital health, health imaging, and generics sectors. Simulations Plus will be combined with Chemical Computing Group after the closing of the transaction.